Current Oncology Reports最新文献

{"title":"Emerging Biomarkers to Predict Immunotherapy Response in Breast Cancer.","authors":"Hannah Maynard, Daisong Liu, Julia Foldi","doi":"10.1007/s11912-025-01710-1","DOIUrl":"https://doi.org/10.1007/s11912-025-01710-1","url":null,"abstract":"","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Circulating Tumor DNA in Patients Treated with Adjuvant Immune Checkpoint Inhibitors: Clinical Reality or Distant Horizon?","authors":"Michele Maffezzoli, Ria Nagpal, Mohamed Elewaily, Lohitha Pedapati, Justin Samuel, Sebastiano Buti, Umberto Malapelle, Akash Maniam, Giuseppe Luigi Banna","doi":"10.1007/s11912-025-01701-2","DOIUrl":"10.1007/s11912-025-01701-2","url":null,"abstract":"","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1055-1069"},"PeriodicalIF":5.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indications of Cannabinoids for the Palliation of Cancer-Associated Symptoms: A Systematic Review and Meta-Analysis.","authors":"Ioana Creangă-Murariu, Ioana-Irina Rezuș, Roshanak Karami, Anett Rancz, Ádám Zolcsák, Marie Anne Engh, Mahmoud Obeidat, Bogdan-Ionel Tamba, Péter Hegyi, Stefania Bunduc","doi":"10.1007/s11912-025-01695-x","DOIUrl":"10.1007/s11912-025-01695-x","url":null,"abstract":"<p><strong>Purpose of the review: </strong>As cancer survival rates are increasing, alternative treatments to improve quality of life, such as cannabinoids, are gaining attention. Although cannabinoids are widely used to manage cancer-related symptoms, clear guidelines are lacking. This systematic review and meta-analysis assessed the safety and efficacy of cannabinoids in the management of symptoms among cancer patients. The study protocol was registered on PROSPERO (CRD42023479375). A systematic search was conducted using three main databases (PubMed, Embase, and CENTRAL) on 4 November 2023. We included interventional and observational studies that evaluated cannabinoids for symptom management in cancer patients compared to standard care, placebo, or baseline values. Pooled mean differences (MD), proportions and odds ratios (OR), and the 95% confidence intervals (CI) were calculated with a random-effects model.</p><p><strong>Recent findings: </strong>Overall, 98 articles were eligible. Cannabinoids reduced pain (MRAW: -1.22, CI: -1.92; -0.52) and anxiety (MRAW: -1.30, CI: -2.22; -0.39) as compared to baseline values. Appetite (MRAW: -1.88, CI: -6.23; 2.46), chemotherapy-induced nausea and vomiting (OR: 2.18, CI: 0.79; 6.00), as well as insomnia (MD: -1.08, CI: -2.48; 0.33) presented with a tendency toward improvement. Cannabinoids do not influence constipation, depression, fatigue, mobility or overall quality of life. In terms of safety issues, THC-predominant formulations increase the risks of psychiatric (OR: 10.62, CI: 1.35; 83.57), neurological (OR:2.24, CI: 1.15; 4.35), and gastrointestinal (OR:2.69, CI:0.73;9.90) side effects. The risk of bias of articles included varied from some concerns to high. Cannabinoids may be beneficial for the treatment of cancer-related pain and anxiety; however, their use carries a significant risk of adverse effects, particularly psychiatric complications. Careful patient selection is essential when considering cannabinoid-based treatments.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1080-1096"},"PeriodicalIF":5.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Plant Terpenoids in Combination with Conventional Therapeutics in Colorectal Cancer: A Promising Option.","authors":"Chengu Niu, Jing Zhang, Patrick I Okolo","doi":"10.1007/s11912-025-01703-0","DOIUrl":"10.1007/s11912-025-01703-0","url":null,"abstract":"","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1054"},"PeriodicalIF":5.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Case for Integration of Health Coaching within Integrative Oncology - Needs, Outcomes, Models, and Standards.","authors":"Rosy Daniel, Julie Bach, Izabella Natrins","doi":"10.1007/s11912-025-01702-1","DOIUrl":"10.1007/s11912-025-01702-1","url":null,"abstract":"<p><strong>Purpose of the review: </strong>This review advocates for the integration of health coaching into oncology care to enhance outcomes for patients, caregivers, healthcare professionals, and oncology services. Health coaching is a person-centred, supportive process that facilitates navigation through trauma, loss, and change while promoting holistic health, physical, emotional, social, and spiritual. It also supports overcoming depression and anxiety by aiding patients in redefining life priorities for health and fulfilment post-treatment.</p><p><strong>Recent findings: </strong>Systematic reviews indicate that health coaching can reduce anxiety and depression in cancer patients, conditions linked with increased cancer recurrence and mortality. Consequently, health coaching holds potential not only to improve quality of life but also to influence cancer morbidity and mortality. The authors' view is that health coaching fills an important gap in oncology services, offering a scalable, cost-effective solution to improve patient outcomes across the cancer continuum. With established global standards and clear competencies, health coaching should be integrated as an essential component of oncology care services.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1106-1113"},"PeriodicalIF":5.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential?","authors":"Yash Patel, Jyotsna Chawla, Mayur S Parmar","doi":"10.1007/s11912-025-01704-z","DOIUrl":"10.1007/s11912-025-01704-z","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review evaluates the scientific evidence for Ivermectin's potential anticancer properties, an antiparasitic drug garnering interest for oncology applications. It assesses the gap between preclinical and clinical evidence and explores implications for healthcare communication based on current evidence.</p><p><strong>Recent findings: </strong>Preclinical studies (in vitro and animal studies) demonstrate Ivermectin's anticancer effects, including inhibition of cancer cell proliferation, induction of apoptosis, and modulation of signaling pathways (e.g., Wnt/β-catenin, Akt/mTOR) across various cancers. However, clinical evidence in humans is limited, with no large-scale randomized controlled trials (RCTs) confirming therapeutic benefits. Observational studies and case reports highlight the risks of self-medication driven by social media touting Ivermectin's unproven cancer benefits, which can lead to toxicity in oncology patients in some cases. The lack of clinical studies creates a critical translational gap between preclinical results and practical clinical application. Despite promising preclinical data, the absence of conclusive large-scale human clinical evidence limits Ivermectin's utility in cancer treatment. Its affordability appeals in resource-limited settings, but ethical challenges arise from misinformation, which may lead patients to forgo proven therapies. Healthcare providers must communicate responsibly to counter misinformation and guide patients toward evidence-based interventions, while supporting rigorous clinical trials to bridge the preclinical-clinical gap.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1070-1079"},"PeriodicalIF":5.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plant Terpenoids in Combination with Conventional Therapeutics in Colorectal Cancer: A Promising Option.","authors":"Chengu Niu, Jing Zhang, Patrick I Okolo","doi":"10.1007/s11912-025-01674-2","DOIUrl":"10.1007/s11912-025-01674-2","url":null,"abstract":"<p><strong>Purpose of review: </strong>Colorectal cancer accounts for approximately 10% of cancer-related mortality in Western countries. The plant-derived terpenoids represent the largest and most diverse class of natural products which possess potent anti-cancer properties in various tumor types. Combination therapy interacts with multiple targets in the molecular networks of colorectal cancer and may achieve synergistic or additive efficacy but reduce adverse side effects. The purpose of this review, mainly based on available preclinical data, is to summarize various plant terpenoids as potential sensitizers to conventional colorectal cancer therapies, along with the challenges and opportunities of these combinations in the clinical application for colorectal cancer treatment.</p><p><strong>Recent findings: </strong>A total of 33 relevant articles were considered for review. This review provided a comprehensive overview of the current state of combining plant terpenoids with conventional therapeutics for colorectal cancer treatment, and discussed the associated therapeutic challenges and opportunities for successfully translating the preclinical findings into clinical settings. We concluded that plant terpenoids as potential adjuvants potentiate the antitumor efficacy of conventional colorectal cancer therapies by inducing apoptosis, reducing senescence, and inhibiting angiogenesis, metastasis, and inflammation through multiple pathways. Hopefully, the knowledge gained from this review will shape future research directions in this field.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1041-1053"},"PeriodicalIF":5.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Treatment Strategies for FLT3-Mutated Acute Myeloid Leukemia in Patients not Candidates for Intensive Chemotherapy.","authors":"Alex Bataller, Nicholas J Short, Naval Daver, Musa Yilmaz, Hagop Kantarjian, Farhad Ravandi","doi":"10.1007/s11912-025-01709-8","DOIUrl":"10.1007/s11912-025-01709-8","url":null,"abstract":"<p><strong>Purpose of review: </strong>Younger patients with acute myeloblastic leukemia with FLT3 mutations (FLT3-mutated AML) benefit from the addition of FLT3 inhibitors to intensive chemotherapy. However, patients who are not eligible for intensive chemotherapy have poor outcomes with standard low-intensity treatments. In this review we assess the current state of treatment strategies for patients with FLT3-mutated AML who are not candidates for intensive chemotherapy.</p><p><strong>Recent findings: </strong>The addition of FLT3 inhibitors to standard low-intensity AML treatments (doublet) has increased response rates, although in a randomized clinical trial this did not improve survival. The addition of venetoclax to these regimens (triplet) shows promising activity (overall response rate of approximately 90%). However, myelotoxicity is common, and dose adjustments are usually necessary. Combinations of low-intensity treatments with venetoclax and potent FLT3 inhibitors are feasible and have shown encouraging outcomes. Dose adjustments are essential to reduce treatment-related myelosuppression.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1097-1105"},"PeriodicalIF":5.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate Cancer Radioligand Therapy: PSMA and Beyond, Current Landscape and Future Directions.","authors":"Eric H Bent, Michael J Morris","doi":"10.1007/s11912-025-01686-y","DOIUrl":"https://doi.org/10.1007/s11912-025-01686-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>There has been a rapid increase in the use and investigation of radioligand therapies for prostate cancer. This review summarizes and synthesizes the current prostate cancer radioligand landscape. It highlights the challenges facing optimal radioligand use and outlines approaches to improve the efficacy of this therapeutic class.</p><p><strong>Recent findings: </strong>The prostate specific membrane antigen (PSMA)-directed radioligand ¹⁷⁷Lu-PSMA-617 improves survival in patients with metastatic castrate resistant prostate cancer (mCRPC) after chemotherapy and is now a standard of care treatment option for these patients. Published and ongoing trials promise to expand the use of radioligand therapies in prostate cancer. These trials highlight the potential of novel radioligand targets, alternate radioisotopes, and combination therapy approaches to improve radioligand efficacy. Emerging radioligands, novel combination therapies, optimized patient selection, and dose-personalization promise to improve outcomes and expand the use of radioligand therapies in prostate cancer.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological Trends in the Characterization of of Human Papillomavirus Virus-Related Oropharyngeal Cancer: A Global Perspective.","authors":"Allen M Chen","doi":"10.1007/s11912-025-01656-4","DOIUrl":"10.1007/s11912-025-01656-4","url":null,"abstract":"<p><strong>Purpose of review: </strong>The incidence of human papillomavirus (HPV)-positive oropharyngeal cancer has increased to epidemic-like proportions in the United States and other industrialized nations. However, geographical variations are notable across the world. While significant progress has been made in the understanding of this disease with respect to its etiology, underlying biology, and pathogenesis, numerous uncertainties persist. The purpose of this review is to thus present some of the controversies and questions surrounding this disease focusing on its unique epidemiology. A selected series of critical points were presented related to the epidemiology, pathogenesis, and diagnosis of HPV-positive oropharyngeal cancer. Interpretive viewpoints were provided after a comprehensive review of the literature.</p><p><strong>Recent findings: </strong>HPV is now estimated to cause approximately 70% of oropharyngeal cancers in the United States and other developed countries. However, in developing countries, the incidence of HPV-positive oropharyngeal cancer is significantly lower. Data has also established that HPV-positive and HPV-negative oropharyngeal cancer represents distinct entities that generally originate in different settings. Since HPV-positive oropharyngeal cancer is increasingly being recognized as a sexually transmitted disease with unique modes of transmission, the epidemiological implications are of practical relevance. The resultant geographical variation in incidence rates among countries across the world is thus believed to be due to differing lifestyles and sexual norms. Although there is currently no role for screening, efforts to promote general awareness particularly among high-risk groups should be prioritized. The development of a novel staging system specific for patients with HPV-positive oropharyngeal cancer also has important ramifications with respect to treatment. HPV-positive oropharyngeal cancer is increasingly recognized as a public health problem with a unique worldwide geographical distribution. As the etiology of this disease is increasingly elucidated, efforts to promote awareness and education are warranted.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144882394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}